Genprex, Inc. (GNPX) News
Filter GNPX News Items
GNPX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest GNPX News From Around the Web
Below are the latest news stories about GENPREX INC that investors may wish to consider to help them evaluate GNPX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning! |
Genprex Granted Orphan Drug Designation in Small Cell Lung CancerLOS ANGELES, CA - (NewMediaWire) - November 23, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Genprex was granted orphan drug designation by the FDA... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! |
Genprex to Present at BIO-Europe 2023LOS ANGELES, CA - (NewMediaWire) - November 03, 2023 - (InvestorBrandNetwork via NewMediaWire) - IBN, a multifaceted financial news, content creation and publishing company, is utilized by both public and private companies to optimize investor awaren... |
Genprex to Present at BIO-Europe 2023 ConferenceGenprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming BIO-Europe 2023 Conference taking place in Munich, Germany. |
Genprex Schedules, Hosts Virtual Key Opinion Leader EventLOS ANGELES, CA - (NewMediaWire) - October 20, 2023 - (InvestorBrandNetwork via NewMediaWire) - IBN, a multifaceted financial news, content creation and publishing company, is utilized by both public and private companies to optimize investor awarene... |
Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will host a virtual key opinion leader (KOL) event highlighting the current state of lung cancer treatments and the challenges facing patients. |
Genprex to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC ConferenceLOS ANGELES, CA - (NewMediaWire) - October 06, 2023 - (InvestorBrandNetwork via NewMediaWire) - IBN, a multifaceted financial news, content creation and publishing company, is utilized by both public and private companies to optimize investor awarene... |
Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGenprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that research collaborators will present positive clinical and preclinical data from studies of its lead product candidate, REQORSA® (quaratusugene ozeplasmid) used for the treatment of lung cancers, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics takin |
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLCNEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation,” please visit: https://nnw.fm/619wq More than 30 million pe |